197 related articles for article (PubMed ID: 10995813)
21. Biomarker discovery in ovarian cancer.
Tung CS; Wong KK; Mok SC
Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
[TBL] [Abstract][Full Text] [Related]
22. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
[TBL] [Abstract][Full Text] [Related]
23. Lights and shadows of the tumoral marker CA-125 in ovarian cancer.
Sánchez Muñoz A; González Martín A; Mendiola Fernández C
Clin Transl Oncol; 2008 Aug; 10(8):449-52. PubMed ID: 18667373
[No Abstract] [Full Text] [Related]
24. [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology].
Sehouli J; Stengel D; Hindenburg J; Camara O; Porzsolt F; Lichtenegger W;
Zentralbl Gynakol; 2001 Mar; 123(3):127-31. PubMed ID: 11340951
[TBL] [Abstract][Full Text] [Related]
25. Origin of ovarian cancer may have implications for screening.
Tuma RS
J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201
[No Abstract] [Full Text] [Related]
26. Ovarian fibroma with marked ascites and elevated serum levels of CA-125 in a young girl.
Sugiyama A; Urushihara N; Fukumoto K; Fukuzawa H; Nagae H; Watanabe K; Mitsunaga M; Hasegawa S; Koyama M
J Pediatr Surg; 2011 May; 46(5):1001-4. PubMed ID: 21616270
[TBL] [Abstract][Full Text] [Related]
27. Epithelial ovarian cancer.
Al-Niaimi AN; Ahmed M; Petersen CB
Obstet Gynecol Clin North Am; 2012 Jun; 39(2):269-83. PubMed ID: 22640715
[No Abstract] [Full Text] [Related]
28. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not.
Dorizzi RM; Meneghelli S; Rocca M; Ferrari A
Clin Chem Lab Med; 2006; 44(11):1386-7; author reply 1388. PubMed ID: 17087656
[No Abstract] [Full Text] [Related]
29. Increased CA 125 in tuberculous peritonitis.
Collazos J
Gut; 1995 Aug; 37(2):297. PubMed ID: 7557589
[No Abstract] [Full Text] [Related]
30. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
31. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer.
Boac BM; Xiong Y; Apte SM; Wenham RM; Shahzad MM; Munroe DG; Lancaster JM; Chon HS
Am J Obstet Gynecol; 2018 Apr; 218(4):436.e1-436.e7. PubMed ID: 29353030
[TBL] [Abstract][Full Text] [Related]
32. The Dangers of Using Tumor Markers to Evaluate Nonspecific Symptoms: A Teachable Moment.
Mortaji P; Lebduska E
JAMA Intern Med; 2020 Jul; 180(7):1004. PubMed ID: 32391883
[No Abstract] [Full Text] [Related]
33. Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine.
Levine DA; Karlan BY; Strauss JF
JAMA; 2016 May; 315(18):1943-4. PubMed ID: 26934631
[No Abstract] [Full Text] [Related]
34. [Assessment of soluble intracellular adhesion molecule-1 (sICAM-1) in women with benign ovarian tumors].
Rzymski P; Opala T; Woźniak J; Drews K; Sajdak S
Ginekol Pol; 2004 Oct; 75(10):785-92. PubMed ID: 15587910
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
Rzymski P; Woźniak J; Opala T; Sajdak S; Drews K
Ginekol Pol; 2002 Nov; 73(11):1090-5. PubMed ID: 12722404
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of clinical evaluation for the level of CA-125 antigen and ultrasonographic color Doppler examination in diagnosis of ovarian tumor].
Czekierdowski A; Zrubek H; Sikorski M; Wiktor H; Józefczak M; Stachowicz N
Ginekol Pol; 1996 Nov; 67(11):552-6. PubMed ID: 9289441
[TBL] [Abstract][Full Text] [Related]
37. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
38. Women with symptoms of ovarian cancer should have a CA125 test, says NICE.
Gulland A
BMJ; 2011 Apr; 342():d2695. PubMed ID: 21525103
[No Abstract] [Full Text] [Related]
39. An unusual abdominal cystic mass.
Montaruli E; Branchereau S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):641; answer 642. PubMed ID: 23018573
[TBL] [Abstract][Full Text] [Related]
40. Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?
Harrison JD; Juraskova I; Anderson C; Nattress K; Beale P; Lopez AL; Carter J
Int J Gynecol Cancer; 2009 Aug; 19(6):1037-46. PubMed ID: 19820365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
